New hope for blood cancer patients: experimental combo aims for deeper remission
NCT ID NCT07228273
Summary
This study is testing whether adding a targeted drug called venetoclax to a standard chemotherapy regimen works better than the current standard treatment for newly diagnosed acute myeloid leukemia (AML). It will involve about 102 adults and aims to see if the new combination leads to a deeper, more lasting remission by killing more cancer cells. The trial is currently recruiting participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.